Regulatory Scrutiny Threatens Kimberly-Clark's Tissue Venture Timeline

UK antitrust inquiry casts doubt on $3.4B Kimberly-Clark & Suzano tissue JV. A Phase 2 probe could delay the mid-2026 closing, impacting shares and strategic plans.

A major joint venture between the American consumer goods giant Kimberly-Clark and Brazil's Suzano pulp and paper company has hit a potential roadblock. The UK's Competition and Markets Authority (CMA) has initiated a formal inquiry into the planned partnership, casting uncertainty over the deal's ambitious completion schedule.

Financial Stakes and Market Position

Announced earlier, the transaction carries an estimated enterprise value of $3.4 billion. Under the proposed terms, Suzano would secure a controlling 51% stake in the combined tissue business, paying Kimberly-Clark approximately $1.734 billion for the majority share. Kimberly-Clark would retain a 49% interest. The joint entity would be a significant global player, operating 22 manufacturing facilities across 14 countries. In 2024, the business to be combined reported net sales of roughly $3.3 billion with an annual production capacity of one million tons.

The UK Investigation's Critical Path

The CMA has now entered a preliminary review phase to assess whether the consolidation could substantially lessen competition within UK markets. The regulator faces a deadline of May 28, 2026, to either clear the deal or escalate its probe to a more intensive "Phase 2" investigation. An extended, in-depth review could significantly delay the transaction's targeted mid-2026 closing date, putting the partners' strategic timeline under considerable pressure.

Share Price Reflects Market Jitters

Uncertainty surrounding the regulatory process has contributed to increased stock price volatility. Kimberly-Clark shares closed Friday's session at €85.72, a level that represents a decline of approximately 17.6% from the 52-week high recorded last October. Technically, the equity appears oversold, with its 14-day Relative Strength Index (RSI) reading at 25.8.

Recent institutional activity has been mixed. While some investors, including Assenagon Asset Management, increased their holdings in late 2025, other major accounts reduced their positions. The outcome of the British antitrust examination is now viewed as a pivotal catalyst for the company's strategic shift. If the CMA raises no objections by the late-May deadline, the goal of finalizing the partnership by summer 2026 remains achievable.